Multidrug-resistant malaria and the impact of mass drug administration

Infection and Drug Resistance

Volumn 11, Issue , 2018, Pages 299-306

  Zuber, Janie Anne ^a   Takala Harrison, Shannon ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Malaria; Mass drug administration

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE; PYRIMETHAMINE; SODIUM CHLORIDE;

ANTIMALARIAL DRUG RESISTANCE; CAMBODIA; DISEASE BURDEN; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; FOOD COMPOSITION; HUMAN; MALARIA CONTROL; MALARIA FALCIPARUM; MASS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; PARASITE TRANSMISSION; PARASITEMIA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRACTICE GUIDELINE; REVIEW; SOUTHEAST ASIA; TANZANIA; THAILAND; WORLD HEALTH ORGANIZATION;

EID: 85042777250     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S123887     Document Type: Review

References (81)

1. WHO. World Malaria Report, 2015. Geneva: WHO; 2015.
2. Gates BC, Chambers, R. From aspiration to action: what will it take to end malaria? Available from: http://endmalaria2040.org/assets/ Aspiration-to-Action.pdf. Accessed October 16, 2017.
3. Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359(24): 2619-2620.
4. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361(5): 455-467.
5. Kyaw MP, Nyunt MH, Chit K, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One. 2013; 8(3): e57689.
6. Hien TT, Thuy-Nhien NT, Phu NH, et al. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J. 2012; 11: 355.
7. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014; 371(5): 411-423.
8. WHO. Strategy for Malaria Elimination in the Greater Mekong Subregion (2015-2030). Geneva: WHO; 2015.
9. Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015; 211(5): 670-679.
10. Miotto O, Amato R, Ashley EA, et al. Genetic architecture of artemisinin- resistant Plasmodium falciparum. Nat Genet. 2015; 47(3): 226-234.
11. World Health Organization Evidence Review Group Meeting Report. Mass Drug Administration, Mass Screening and Treatment and Focal Screening and Treatment for Malaria. Geneva: World Health Organization; 2015.
12. Barber MA, Rice JB, Brown JY. Malaria studies on the Firestone rubber plantation in Liberia, West Africa. Am J Hyg. 1932; 15(3): 601-633.
13. Snowden FM. The Conquest of Malaria; Italy, 1900-1962. New Haven: Yale University Press; 2006.
14. Dixon DS. Paludrine (proguanil) as a malarial prophylactic amongst African labour in Kenya. East Afr Med J. 1950; 27(3): 127-130.
15. Molineaux L, Gramiccia G. The Garki Project: Research on the Epidemiology and Control of Malaria in the Sudan Savanna of West Africa. Geneva: World Health Organization; 1980.
16. von Seidlein L, Walraven G, Milligan PJ, et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg. 2003; 97(2): 217-225.
17. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Björkman A. Malaria eradication on islands. Lancet. 2000; 356(9241): 1560-1564.
18. malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 2011; 8(1): e1000402.
19. Dola SK. Mass drug administration as a supplementary attack measure in malaria eradication programme. East Afr Med J. 1974; 51(7): 529-531.
20. von Seidlein L, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol. 2003; 19(10): 452-460.
21. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev. 2013;(12): CD008846.
22. Newby G, Hwang J, Koita K, et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg. 2015; 93(1): 125-134.
23. Pinotti M. The addition of antimalarial drugs to cooking salt: its importance in malaria eradication programmes. Triangle. 1959; 4: 119-113.
24. D’Alessandro U, Buttiens H. History and importance of antimalarial drug resistance. Trop Med Int Health. 2001; 6(11): 845-848.
25. Eyles DE, Hoo CC, Warren M, et al. Plasmodium falciparum resistant to chloroquine in Cambodia. Am J Trop Med Hyg. 1963; 12: 840-8433.
26. Giglioli G, Rutten FJ, Ramjattan S. Interruption of malaria transmission by chloroquinized salt in Guyana, with observations on a chloroquineresistant strain of Plasmodium falciparum. Bull World Health Organ. 1967; 36(2): 283-301.
27. Hall SA, Wilks NE. A trial of chloroquine-medicated salt for malaria suppression in Uganda. Am J Trop Med Hyg. 1967; 16(4): 429-442.
28. Plowe CV. The evolution of drug-resistant malaria. Trans R Soc Trop Med Hyg. 2009; 103(suppl 1): S11-S14.
29. Payne D. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol Today. 1988; 4(4): 112-115.
30. Clyde DF, Shute GT. Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Trans R Soc Trop Med Hyg. 1957; 51(6): 505-513.
31. Charles LJ, Van Der Kaay HJ, Vincke IH, Brady J. The appearance of pyrimethamine resistance in Plasmodium falciparum following selfmedication by a rural community in Ghana. Bull World Health Organ. 1962; 26: 103-108.
32. Denis MB, Tsuyuoka R, Lim P, et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006; 11(12): 1800-1807.
33. Denis MB, Tsuyuoka R, Poravuth Y, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2006; 11(9): 1360-1366.
34. Lwin KM, Imwong M, Suangkanarat P, et al. Elimination of Plasmodium falciparum in an area of multi-drug resistance. Malar J. 2015; 14: 319.
35. Hastings IM, Watkins WM, White NJ. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci. 2002; 357(1420): 505-519.
36. Nyunt MM, Plowe CV. Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance. Clin Pharmacol Ther. 2007; 82(5): 601-605.
37. Kay K, Hastings IM. Measuring windows of selection for anti-malarial drug treatments. Malar J. 2015; 14: 292.
38. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother. 2008; 52(5): 1589-1596.
39. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother. 2000; 44(8): 2100-2108.
40. Maude RJ, Nguon C, Dondorp AM, White LJ, White NJ. The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment. Malar J. 2014; 13: 380.
41. Imwong M, Suwannasin K, Kunasol C, et al. The spread of artemisininresistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis. 2017; 17(5): 491-497.
42. Leang R, Taylor WR, Bouth DM, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015; 59(8): 4719-4726.
43. Spring MD, Lin JT, Manning JE, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015; 15(6): 683-691.
44. Wernsdorfer WH. The biological and epidemiological basis of drug resistance in malaria parasites. Southeast Asian J Trop Med Public Health. 1992; 23(suppl 4): 123-129.
45. White NJ, Pongtavornpinyo W, Maude RJ, et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J. 2009; 8: 253.
46. Verdrager J. Epidemiology of emergence and spread of drug-resistant falciparum malaria in Southeast Asia. Southeast Asian J Trop Med Public Health. 1986; 17(1): 111-118.
47. Bethell D, Se Y, Lon C, et al. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One. 2011; 6(5): e19283.
48. Hastings IM, Paget-McNicol S, Saul A. Can mutation and selection explain virulence in human P. falciparum infections? Malar J. 2004; 3: 2.
49. Phyo AP, Ashley EA, Anderson TJC, et al. Declining efficacy of Artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar Border (2003-2013): the role of parasite genetic factors. Clin Infect Dis. 2016; 63(6): 784-791.
50. World Wide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015; 13: 227.
51. Djimde AA, Doumbo OK, Traore O, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003; 69(5): 558-563.
52. White NJ. Does antimalarial mass drug administration increase or decrease the risk of resistance? Lancet Infect Dis. 2017; 17(1): e15-e20.
53. Straimer J, Gnadig NF, Witkowski B, et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015; 347(6220): 428-431.
54. Hastings IM, Hodel EM. Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough? Malar J. 2014; 13: 62.
55. Burrows JN, van Huijsduijnen RH, Möhrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013; 12: 187.
56. Kremsner PG, Krishna S. Antimalarial combinations. Lancet. 2004; 364(9430): 285-294.
57. Peel SA, Bright P, Yount B, Handy J, Baric RS. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. Am J Trop Med Hyg. 1994; 51(5): 648-658.
58. Amato R, Lim P, Miotto O, et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect Dis. 2017; 17(2): 164-173.
59. Witkowski B, Duru V, Khim N, et al. A surrogate marker of piperaquineresistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis. 2017; 17(2): 174-183.
60. Phuc BQ, Rasmussen C, Duong TT, et al. Treatment failure of dihydroartemisinin/ piperaquine for Plasmodium falciparum Malaria, Vietnam. Emerg Infect Dis. 2017; 23(4): 715-717.
61. Rasmussen C, Ariey F, Fairhurst RM, et al. Role of K13 mutations in artemisinin-based combination therapy. Clin Infect Dis. 2016; 63(12): 1680-1681.
62. Rossi G, De Smet M, Khim N, et al. Emergence of Plasmodium falciparum triple mutant in Cambodia. Lancet Infect Dis. 2017; 17(12): 1233.
63. Maxmen A. Back on TRAC: new trial launched in bid to outpace multidrug-resistant malaria. Nat Med. 2016; 22(3): 220-221.
64. Chotsiri P, Wattanakul T, Hoglund RM, et al. Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Br J Clin Pharmacol. 2017; 83(12): 2752-2766.
65. Tesh RB, Guzman H. Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin. Am J Trop Med Hyg. 1990; 43(3): 229-233.
66. Chaccour C, Lines J, Whitty CJ. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 2010; 202(1): 113-116.
67. Foy BD, Kobylinski KC, da Silva IM, Rasgon JL, Sylla M. Endectocides for malaria control. Trends Parasitol. 2011; 27(10): 423-428.
68. Kobylinski KC, Deus KM, Butters MP, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010; 116(2): 119-126.
69. Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg. 2011; 85(1): 3-5.
70. Kobylinski K. Safety and mosquito-lethal efficacy of ivermectin, dihydroartemisinin- piperaquine, and primaquine: Ivermectin for Malaria in Southeast Asia (IMSEA Study, Thailand). In: American Society of Tropical Medicine and Hygiene Annual Meeting; Atlanta, GA; 2016.
71. Omura S, Crump A. Ivermectin and malaria control. Malar J. 2017; 16(1): 172.
72. Chaccour CJ, Kobylinski KC, Bassat Q, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J. 2013; 12: 153.
73. Panchal M, Rawat K, Kumar G, et al. Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleo-cytoplasmic shuttling of SRP. Cell Death Dis. 2014; 5: e994.
74. Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO, Prichard RK. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis. 2011; 5(3): e998.
75. Smits HL. Prospects for the control of neglected tropical diseases by mass drug administration. Expert Rev Anti Infect Ther. 2009; 7(1): 37-56.
76. Pérez del Villar L, Burguillo FJ, López-Abán J, Muro A. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One. 2012; 7(9): e45867.
77. Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs. 2007; 8(2): 105-116.
78. Utzinger J, Tanner M, Keiser J. ACTs for schistosomiasis: do they act? Lancet Infect Dis. 2010; 10(9): 579-581.
79. Hsiang M, Hwang J, Tao A, et al. Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J. 2013; 12: 383.
80. Robinson LJ, Wampfler R, Betuela I, et al. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean Children: a randomised placebocontrolled trial and mathematical model. PLoS Med. 2015; 12(10): e1001891.
81. Landier J, Kajeechiwa L, Thwin MM, et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisininresistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Res. 2017; 2: 81.